{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Coherus BioSciences, Inc."},"Symbol":{"label":"Symbol","value":"CHRS"},"Address":{"label":"Address","value":"333 TWIN DOLPHIN DRIVE,SUITE 600, REDWOOD CITY, California, 94065, United States"},"Phone":{"label":"Phone","value":"+1 650 649-3530"},"Industry":{"label":"Industry","value":"Biotechnology: Biological Products (No Diagnostic Substances)"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an innovative immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. Toripalimab is being evaluated in pivotal clinical trials for the treatment of cancers of the lung, breast, liver, skin, kidney, stomach, esophagus, and bladder. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company is also developing CHS-305, a biosimilar of Avastin. The company generates revenue primarily from the United States."},"CompanyUrl":{"label":"Company Url","value":"https://www.coherus.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Denny M. Lanfear","title":"Chairman, President & Chief Executive Officer"},{"name":"Richard L. Hameister","title":"Chief Technical Officer"},{"name":"Rosh Dias","title":"Chief Medical Officer"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}